With Karuna’s schizophrenia program coined as the most anticipated drug launch of 2024, and 2023 bringing brand new regulatory guidance, surging investment has reinvigorated the space with new targets, mechanisms, and technologies to transform the mental health treatment landscape.

Capitalizing on a new wave of pipeline momentum, the 7th Neuropsychiatric Drug Development Summit returns as the industry’s premier gathering, showcasing the latest circuit-based target innovation, EEG and digital biomarker data, in vivo and in vitro model advances, pioneering precision psychiatry approaches and more.

Join discovery, preclinical, translational, clinical, regulatory, and commercial experts from Karuna, Janssen, AbbVie, Otsuka, Alto Neuroscience, Lykos, Lundbeck, Compass, Biogen, DelixTherapeutics, Boehringer Ingelheim, and more as they address biopharma’s most pressing challenges in a collaborative atmosphere to accelerate the race to approval for transformative neuropsychiatric candidates.

Event Link here.